Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ANTIBODY LICENSE AGREEMENTAntibody License Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • New York
This Antibody License Agreement (“Agreement”) is entered into effective December 20, 2012 (“Effective Date”) by Open Monoclonal Technologies, Inc. (“OMT”), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (“Licensee”), a Delaware limited liability company, having its principal place of business at [***].
1 EXHIBIT 10.8 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION] ANTIBODY LICENSE AGREEMENT THIS AGREEMENT, dated September 22, 1995, is entered into by and...Antibody License Agreement • February 10th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances
